On June 18, 2026, analyst firm Barclays initiated coverage on INDIVIOR PLC (NASDAQ: INDV), assigning it an "Overweight" rating when the stock price was $37.93. An Overweight rating suggests that the analyst believes the pharmaceutical stock will perform better than others in its sector. Indivior PLC is a pharmaceutical company focused on addiction treatment and mental illness treatments.
The positive outlook is supported by a market shift toward long-acting injectable treatments for opioid use disorder, as highlighted by Zacks Investment Research. Indivior PLC is a key player in this area with its main product, Sublocade. These monthly treatments can improve patient adherence to their care plans compared to daily medications.
Sublocade holds a dominant 76% share of its category and is secured by over 88% payer coverage, meaning most insurance plans cover it. Despite this, the adoption of these treatments is only at 9% market penetration. This low figure indicates a significant growth opportunity for Indivior PLC as more patients switch to long-acting options.
This market position is reflected in the company's strong financial results. Indivior PLC reported a 113.3% year-over-year increase in adjusted earnings to $0.96 per share for the first quarter, beating estimates. This performance led the company to raise its 2026 guidance for revenue and EBITDA, a measure of profitability.
The growth was driven by a 32% rise in Sublocade revenue, helped by higher sales volume and better pricing. To improve its financial health, Indivior PLC also repurchased its own shares and refinanced its debt to lower interest costs. These actions show a focus on maintaining financial strength while expanding its market.
